XML 131 R6.htm IDEA: XBRL DOCUMENT v3.24.4
Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Cash flows used in operating activities        
Net loss $ (8,978,129) $ (8,030,256) $ (13,763,658) $ (12,073,260)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 60,825 63,359 84,479 90,923
Accretion of discount on convertible debentures 64,101 24,273
Accrued expenditures for government grant 23,767 (80,000)
Accrued interest 5,476 8,230
Accrue interest expense, convertible debentures 8,716    
Accrued interest income, related party 2,550 (886) (2,550)
Change in fair value of conversion feature liability (174,930)    
Change in fair value of warrant liabilities 16,127 532,429 4,085,284 (1,823,444)
Change in fair value of bonus rights liability (9,875) 5,246 75,830 8,295
Debt issuance costs 354,791    
Provision for loan losses 55,000    
Impairment of intangible assets 39,166    
Share-based compensation 917,153 1,899,429 2,369,585 1,777,271
Loss on write-off of equipment     5,506
Shares issued for services 2,273,949    
Changes in non-cash operating working capital items:        
Prepaid expenses and other current assets (454,617) 68,761 (117,271) 619,787
Accounts payable and accrued liabilities 349,478 (1,312,729) (1,451,264) 2,110,301
Net cash used in operating activities (5,451,927) (6,769,171) (8,799,565) (9,252,118)
Cash flows provided by (used in) investing activities        
Acquisition of equipment     (4,876)
Net cash provided by (used in) investing activities (4,876)
Cash flows provided by financing activities        
Units issued for cash 3,732,469 5,851,148 9,223,587
Exercise of options 1,800 10,500 27,000 40,785
Exercise of warrants 300,000    
Proceeds received from restricted government grant 373,825 201,500 201,500
Amounts paid from restricted government grant funds (357,228) (111,087)
Issuance of related party note (55,000) (55,000)
Proceeds from issuance of convertible debentures 4,545,000    
Debt issuance costs (459,360)    
Share issuance costs (405,753) (394,736) (1,055,985)
Net cash provided by financing activities 7,730,753 5,613,412 8,230,015 40,785
Effect of foreign exchange on cash (19,573) (19,573) (1,888)
Change in cash and cash equivalents during the period 2,278,826 (1,175,332) (589,123) (9,218,097)
Cash and cash equivalents, beginning of period 1,494,573 2,083,696 2,083,696 11,301,793
Cash and cash equivalents, end of period 3,773,399 908,364 1,494,573 2,083,696
Cash and cash equivalents consists of:        
Demand deposits 3,666,389 706,864    
Cash     1,404,160 2,083,696
Restricted cash 107,010 201,500 90,413
Total cash and cash equivalents 3,773,399 908,364 1,494,573 2,083,696
Supplemental Disclosure        
Cash paid for interest 37,754 53,991 59,777 16,000
Supplemental non-cash disclosures        
Reallocation of fair value of share options upon exercise 126,382 676,632 1,424,519 206,382
Reclassification of derivative liability for warrants priced with USD per change in functional currency 351,969 351,969
Reclassification of derivative liability for warrants priced with CAD per change in functional currency 4,541,545 4,541,545
Reclassification of derivative liability for warrants re-priced from CAD to USD exercise price 3,942,575 4,025,102
Common shares issued for share issuance costs 928,874 618,004
Warrants issued for share issuance costs 582,245 117,310 $ 402,166
Common shares issued for services $ 2,273,949